Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pfizer (PFE)

Pfizer Reports Q3 2026 Revenues of $16.6 Billion and Raises Full-Year Guidance

Positive Impact 4 of 5 guidance

Pfizer announced third-quarter 2026 revenues of $16.6 billion, matching the prior-year period operationally, while reporting adjusted diluted EPS of $0.87. Driven by solid performance in non-COVID and newly launched products, the company raised its full-year 2026 revenue guidance to a range of $62.0 to $64.0 billion and narrowed its adjusted diluted EPS guidance to $2.95 to $3.05. Shareholders also saw the appointment of Cecile Guegan as Chief Financial Officer and Executive Vice President.

Key points

  • Third-quarter 2026 revenues reached $16.6 billion, with non-COVID products growing 7% operationally.
  • Full-year 2026 revenue guidance was raised by $1.5 billion at the midpoint to $62.0 to $64.0 billion.
  • Adjusted diluted EPS guidance for full-year 2026 was raised and narrowed to $2.95 to $3.05.
  • Cecile Guegan was appointed Chief Financial Officer and Executive Vice President effective November 1, 2026.

The filing

CompanyPfizer (PFE)
Form8-K, current report
Filed with the SECNov 3, 2026, 8:07 AM ET
Accession number0000078003-26-000125

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Google Gemini, gemini-3.5-flash-lite) on Nov 3, 2026, 8:16 AM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.